New osteoporosis drug approved in Europe (Reuters, 5 October 2007)

10 Oct 2007

Novartis AG have announced that their drug Aclasta had been approved by the European Commission for once-yearly treatment of women with post-menopausal osteoporosis. Aclasta, which is administered annually in a 15-minute infusion, is already approved in the United States, where it is sold as Reclast.